Navigation Links
Beckman Coulter Announces Third Quarter 2009 Results
Date:10/29/2009

nce costs (11.8) - Net cash provided by (used in) financing activities 765.3 (45.9) Effect of exchange rates on cash and cash equivalents 2.9 (0.8) Change in cash and cash equivalents 142.3 (11.6) Cash and cash equivalents-beginning of period 120.0 83.0 Cash and cash equivalents-end of period $262.3 $71.4 

                              BECKMAN COULTER, INC
                              SEGMENT REVENUES (1)
                                 (in millions)
                                   (unaudited)

                                       Quarter Ended
                                        September 30,
                                        -------------               Constant
                                                          Reported  Currency
                                        2009      2008    Growth%   Growth%(2)
    Clinical Diagnostics(3)
      Chemistry and Clinical
       Automation                     $282.7    $220.4     28.3%     32.0%
      Cellular Analysis                229.0     233.1     (1.7)%     0.7%
      Immunoassay and Molecular
       Diagnostics                     199.3     182.4      9.3%     13.1%
        Total Clinical Diagnostics     711.0     635.9     11.8%     15.1%
    Life Sciences                      111.8     122.9     (9.0)%    (6.8)%
          Total revenues              $822.8    $758.8      8.4%     11.6%

                                     Nine Months Ended
                                        September 30,
                                        -------------              Constant
                                                         Reported  Currency
                                        2009      2008   Growth %  Growth %(2)
    Clinical Dia
'/>"/>
SOURCE  Beckman Coulter, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 

Related medicine technology :

1. Beckman Coulter Announces Licensing Agreements for Molecular Tests with National University of Ireland, Galway
2. Beckman Coulter Buys Out Royalty Obligation for Preeclampsia Markers
3. Beckman Coulter to Present at Upcoming Healthcare Conferences
4. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
5. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
6. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
7. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
8. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
9. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
10. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
11. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... -- Intercept Pharmaceuticals, Inc.  (NASDAQ: ICPT ), a ... commercialization of novel bile acid therapeutics to treat chronic ... public offering of 1,730,000 shares of its common stock ... In addition, Intercept has granted the underwriters a 30-day ... of common stock. All of the shares ...
(Date:6/18/2013)... 18, 2013  Actavis, Inc. (NYSE: ACT ) ... the U.S. Securities and Exchange Commission (SEC) a registration statement ... Warner Chilcott plc (NASDAQ: WCRX ), ... Warner Chilcott (the "Form S-4"). As previously ... have entered into a definitive agreement pursuant to which ...
(Date:6/18/2013)... , June 18, 2013  Recent regulatory and ... for Medical Education groups at large pharmaceutical companies to ... safe and effective use of their new products. With ... industry, it is crucial that these "Med Ed" ... professionals. To address the changes that are ...
Breaking Medicine Technology:Intercept Pharmaceuticals Announces Pricing of Public Offering of Common Stock 2Actavis Files Registration Statement on Form S-4 in Connection with Proposed Warner Chilcott Acquisition 2Actavis Files Registration Statement on Form S-4 in Connection with Proposed Warner Chilcott Acquisition 3Actavis Files Registration Statement on Form S-4 in Connection with Proposed Warner Chilcott Acquisition 4Actavis Files Registration Statement on Form S-4 in Connection with Proposed Warner Chilcott Acquisition 5Actavis Files Registration Statement on Form S-4 in Connection with Proposed Warner Chilcott Acquisition 6Actavis Files Registration Statement on Form S-4 in Connection with Proposed Warner Chilcott Acquisition 7Though Vital to Educating Doctors on New Products, Pharma "Med Ed" Groups Working Under Huge Internal & External Constraints 2
... Muscular Dystrophy Association ( MDA ) has awarded $750,000 to ... development of an experimental drug that may become a viable ... The funding comes from MDA Venture Philanthropy (MVP), ... is one of nine types of muscular dystrophy, a group ...
... panel of experts has recommended changes to the guidelines ... suffering from severe chronic pain. The 2011 Polyanalgesic Consensus ... in chronic pain management for the purpose of updating ... improving the technical quality of care in chronic pain. ...
Cached Medicine Technology:MDA Awards $750,000 to Help Summit Test New Drug Formulation in Phase 1 Clinical Trial of Potential Treatment for Duchenne Muscular Dystrophy 2MDA Awards $750,000 to Help Summit Test New Drug Formulation in Phase 1 Clinical Trial of Potential Treatment for Duchenne Muscular Dystrophy 3MDA Awards $750,000 to Help Summit Test New Drug Formulation in Phase 1 Clinical Trial of Potential Treatment for Duchenne Muscular Dystrophy 42011 Consensus Panel Issues New Guidelines for Intrathecal Pain Management 22011 Consensus Panel Issues New Guidelines for Intrathecal Pain Management 32011 Consensus Panel Issues New Guidelines for Intrathecal Pain Management 42011 Consensus Panel Issues New Guidelines for Intrathecal Pain Management 52011 Consensus Panel Issues New Guidelines for Intrathecal Pain Management 6
(Date:6/19/2013)... Scott Tischler of Tischler Brothers Fitness unveils how to kick ... very first thing that should be done every morning is ... The body is dehydrated when it first wakes up and ... and will also kick start the metabolism first thing in ... the water to body temperature before it can be digested ...
(Date:6/19/2013)... According to Vanessa Grigoriadis, a contributing ... are creating new designer drugs featuring psychoactive effects by ... documents and patented formulas. She reported her findings to ... on June 4. , “Some of these drugs could ... on humans. Maybe some of them are tested on ...
(Date:6/19/2013)... (PRWEB) June 19, 2013 As Mirena ... LLP highlights a recent news story from an NBC ... effects of the hormone-based contraceptive device. The Rottenstein Law ... to file Mirena lawsuits and who are ... The U.S. Food and Drug Administration has logged more ...
(Date:6/19/2013)... Sudden cardiac arrest can strike anyone, even a child, at ... minutes after cardiac arrest, but the average emergency medical service ... is highly probable if an automated external defibrillator or ... to this dire reality, US Representative Lois Capps (CA-24) has ... which would provide support for AED and CPR training programs ...
(Date:6/19/2013)... (PRWEB) June 19, 2013 Transvaginal mesh lawsuits ... matter. A May 31 order addressed how to handle evidence ... preserve and test samples and device components removed from patients. ... informational website , complete with news about the device and ... are to obtain the samples from the medical facilities that ...
Breaking Medicine News(10 mins):Health News:Dangerous Designer Drugs Dodge Legal System 2Health News:Dangerous Designer Drugs Dodge Legal System 3Health News:Rottenstein Law Group LLP Comments on News Reports of Mirena IUD Side Effects 2Health News:AED.com Supports Automated External Defibrillator (AED) Legislation in Schools in US and UK 2Health News:Transvaginal Mesh Lawsuit News: NJ Mesh Consolidation Cases Moving Along, Rottenstein Law Group LLP Reports 2
... 11 MedImmune, the,global biologics unit of AstraZeneca, ... Holdings, Inc., announced today that they have entered,into ... commercialize,SBI Biotech,s anti-ILT7 protein for the potential treatment ... MedImmune has,global rights to any resulting product candidates ...
... back,to school, parents gain flexibility in what their ... Department of Agriculture (USDA),announced parents or legal guardians ... cow,s milk for children receiving National School Lunch ... growing diversity of,participants in the School Nutrition Programs ...
... Sept. 11 /Xinhua-PRNewswire-FirstCall/ -- Genesis,Pharmaceuticals Enterprises, Inc. (OTC ... pharmaceutical company in the People,s Republic,of China, today ... a,total value of approximately $12 million over the ... the 43rd Annual New Drugs Conference (the,"Conference") sponsored ...
... MIT study suggests , , THURSDAY, Sept. 11 (HealthDay News) -- ... your eyes. , A team of neuroscientists publishing ... they have tricked the brain into confusing one object the ... humans to learn to recognize objects. , People never really ...
... waiting room time more enjoyable and informative for patients, ... and helping doctors become more profitable in the process. ... is Ear, Nose & Throat Associates of South Florida ... month in Chicago at AOA-26 and OTO EXPO and ...
... NBTY, Inc. (NYSE:,NTY) (http://www.NBTY.com ), a leading global ... will web cast the,presentation by Harvey Kamil, President and ... Ideas Conference in New York on Wednesday,September 17, 2008., ... live on NBTY,s web site, (http://www.nbty.com ) on Wednesday, ...
Cached Medicine News:Health News:MedImmune Further Expands Autoimmune Disease Research Program Through Collaboration with SBI Biotech 2Health News:Parents Can Now Ask Schools to Serve Soymilk 2Health News:Genesis Pharmaceuticals Received New Purchase Orders Worth $12 Million 2Health News:Genesis Pharmaceuticals Received New Purchase Orders Worth $12 Million 3Health News:Time Teaches Brain to Recognize Objects 2Health News:Mediplay Makes Marketing More Profitable For Physicians 2Health News:Mediplay Makes Marketing More Profitable For Physicians 3Health News:NBTY to Web Cast Presentation at CL King Best Ideas Conference 2
... Medline Has the Right Solution For ... tracheostomy clean and care tray features the ... of this important infection control task. Designed ... the individual needs of each patient and ...
... the Right Solution For Your Tracheostomy Care ... care tray features the latest components for ... infection control task. Designed by clinicians, these ... of each patient and caregiver. All of ...
... alternate care facilities with a wide ... offer the finest in nursing convenience ... guidance of experienced nursing personnel, these ... is required for efficient and quick ...
... Kendall provides hospitals and alternate ... of tracheostomy care trays which offer ... infection control. Designed with the guidance ... total-care trays provide exactly what is ...
Medicine Products: